Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks

Completed · Phase 2 · Has a placebo group

Conditions studied: HIV Infections, Heart Disease

In brief

The hypothesis of this study is that 96 weeks of Rosuvastatin will be safe and effective in decreasing cardiovascular risk and bone loss in the HIV+ population.

Key facts

Study ID
NCT01218802
Run by
University Hospitals Cleveland Medical Center
People needed
147
Starts
2011-02-01
Expected to finish
2014-05-01
Last updated by the study team
2016-03-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.